A citation-based method for searching scientific literature

Samuel A Wells, Bruce G Robinson, Robert F Gagel, Henning Dralle, James A Fagin, Massimo Santoro, Eric Baudin, Rossella Elisei, Barbara Jarzab, James R Vasselli, Jessica Read, Peter Langmuir, Anderson J Ryan, Martin J Schlumberger. J Clin Oncol 2012
Times Cited: 839

V Subbiah, V Velcheti, B B Tuch, K Ebata, N L Busaidy, M E Cabanillas, L J Wirth, S Stock, S Smith, V Lauriault, S Corsi-Travali, D Henry, M Burkard, R Hamor, K Bouhana, S Winski, R D Wallace, D Hartley, S Rhodes, M Reddy, B J Brandhuber, S Andrews, S M Rothenberg, A Drilon. Ann Oncol 2018
Times Cited: 178

List of shared articles

Times cited

Medullary thyroid cancer - An update.
Laura Fugazzola. Best Pract Res Clin Endocrinol Metab 2022

Targeted therapy and drug resistance in thyroid cancer.
Yujie Zhang, Zhichao Xing, Tianyou Liu, Minghai Tang, Li Mi, Jingqiang Zhu, Wenshuang Wu, Tao Wei. Eur J Med Chem 2022

Multiple endocrine neoplasia type 2: A review.
Jes Sloth Mathiesen, Grigoris Effraimidis, Maria Rossing, Åse Krogh Rasmussen, Lise Hoejberg, Lars Bastholt, Christian Godballe, Peter Oturai, Ulla Feldt-Rasmussen. Semin Cancer Biol 2022

Real-world insights into the efficacy and safety of tyrosine kinase inhibitors against thyroid cancers.
Lingyu Li, Lin Cheng, Ri Sa, Xian Qiu, Libo Chen. Crit Rev Oncol Hematol 2022

Resistance to RET targeted therapy in Thyroid Cancer: Molecular basis and overcoming strategies.
María San Román-Gil, Javier Pozas, Diana Rosero-Rodríguez, Jesús Chamorro-Pérez, Álvaro Ruiz-Granados, Ignacio Ruz Caracuel, Enrique Grande, Javier Molina-Cerrillo, Teresa Alonso-Gordoa. Cancer Treat Rev 2022

Sporadic Medullary Thyroid Carcinoma: Towards a Precision Medicine.
Antonio Matrone, Carla Gambale, Alessandro Prete, Rossella Elisei. Front Endocrinol (Lausanne) 2022

New Horizons: Emerging Therapies and Targets in Thyroid Cancer.
Matthew D Ringel. J Clin Endocrinol Metab 2021

Kinase gene fusions: roles and therapeutic value in progressive and refractory papillary thyroid cancer.
Mian Liu, Pei Chen, Hui-Yu Hu, Deng-Jie Ou-Yang, Rooh-Afza Khushbu, Hai-Long Tan, Peng Huang, Shi Chang. J Cancer Res Clin Oncol 2021

Anlotinib in Locally Advanced or Metastatic Medullary Thyroid Carcinoma: A Randomized, Double-Blind Phase IIB Trial.
Dapeng Li, Yihebali Chi, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng,[...]. Clin Cancer Res 2021

Progress in Treating Advanced Thyroid Cancers in the Era of Targeted Therapy.
Carrie C Lubitz, Peter M Sadow, Gilbert H Daniels, Lori J Wirth. Thyroid 2021

ATF4 loss of heterozygosity is associated with poor overall survival in medullary thyroid carcinoma.
Michelle D Williams, Junsheng Ma, Elizabeth G Grubbs, Robert F Gagel, Rozita Bagheri-Yarmand. Am J Cancer Res 2021

Targeted activity of the small molecule kinase inhibitor Pz-1 towards RET and TRK kinases.
Marialuisa Moccia, Donglin Yang, Naga Rajiv Lakkaniga, Brendan Frett, Nicholas McConnell, Lingtian Zhang, Annalisa Brescia, Giorgia Federico, Lingzhi Zhang, Paolo Salerno,[...]. Sci Rep 2021

Precision therapy for RET-altered cancers with RET inhibitors.
Kyaw Z Thein, Vamsidhar Velcheti, Blaine H M Mooers, Jie Wu, Vivek Subbiah. Trends Cancer 2021

Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development.
Debasmita Saha, Katie Rose Ryan, Naga Rajiv Lakkaniga, Baku Acharya, Noemi Garcia Garcia, Erica Lane Smith, Brendan Frett. J Med Chem 2021

[Molecular genotyping in refractory thyroid cancers in 2021: When, how and why? A review from the TUTHYREF network].
Christelle de la Fouchardière, Johanna Wassermann, Fabien Calcagno, Stéphane Bardet, Abir Al Ghuzlan, Isabelle Borget, Françoise Borson Chazot, Christine Do Cao, Camille Buffet, Slimane Zerdoud,[...]. Bull Cancer 2021